Ron Ziegler
This article was originally published in The Tan Sheet
Executive Summary
Former National Association of Chain Drug Stores CEO Ronald Ziegler died of a heart attack Feb. 10 at the age of 63. Ziegler served as head of NACDS from January 1988 until February 1999, when he left the association for health reasons (1"The Tan Sheet" Feb. 15, 1999, p. 24). Under his leadership, NACDS quadrupled in size from $7 mil. in revenues and 25 staffers to over $28 mil. in revenues and 95 employees by the end of his tenure. Ziegler, who was living in Coronado, Calif. at the time of his death, is survived by his wife Nancy, his mother and two daughters...
You may also be interested in...
NACDS
Robert Hannan will serve as interim president and CEO following Ronald Ziegler's retirement Feb. 28. Hannan was president and CEO of Thrift Drug for 10 years until the chain was acquired by J.C. Penney and merged with Eckerd in 1997. After serving as Eckerd vice chairman during the transition, Hannan retired in 1998. He was NACDS chairman from 1993 to 1994. Ziegler will retire at the end of February "because of health reasons," NACDS announces Feb. 8. Ziegler previously said he would retire in December 2000 after a successor was named ("The Tan Sheet" Feb. 1, p. 27). However, in a series of meetings with the association board in Miami, "he concluded that it was in his best interest to initiate his retirement sooner than originally planned," NACDS says. The association emphasizes that "Ziegler and the entire board hold one another in the highest regard and in the highest terms of respect"
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.